- High BMI is an unfavorable prognostic indicator for relapse-free survival (RFS) in patients undergoing R0 gastrectomy for stage II/III gastric cancer (GC).
Why this matters
- The incidence of obesity continues to increase globally.
- Study to investigate a relationship between BMI and outcomes in patients with stage II/III GC who underwent elective open R0 gastrectomy.
- Mean patient age, 67.8 (range, 31-88) years.
- Postoperative adjuvant chemotherapy was administered per Japanese gastric cancer treatment guidelines.
- Patients were stratified by BMI:
- 2: n=64.
- 18.5-25 kg/m2: n=320.
- ≥25 kg/m2: n=76.
- Funding: None disclosed.
- 5-year RFS by BMI:
- 2: 47.6%.
- 18.5-25 kg/m2: 54.3%.
- ≥25 kg/m2: 40.1%
- In patients with BMI ≥25.0 kg/m2 vs those with BMI 2, HR for relapse is 1.42 (95% CI, 1.0-2.02; P=.0423).
- Inferior survival in patients with BMI >25.0 kg/m2 vs 2 (P=.076).
- BMI >25.0 kg/m2 was associated with:
- longer operation time (P=.0610),
- increased blood loss (P=.0003), and
- fewer lymph nodes dissected (P=.1894).
- Patients with BMI >25.0 kg/m2 were more likely to experience postoperative complications, surgical site infection, and intra-abdominal abscess.
- Retrospective data.